How Is Exosomes Measured?
Exosome measurement in research spans urine, blood, and cell-culture models, using podocyte-specific proteins, microRNA cargo, and nanoparticle tracking. This page summarises the methods and the studies that use them.
How Is Exosomes Measured?
Exosomes are measured by isolating them from a biological fluid or conditioned medium and then quantifying either their physical properties or their molecular cargo. The formal name for the vesicle class is extracellular vesicles (EVs), of which exosomes are the endosome-derived subset; common synonyms in the literature include small EVs and exosomal vesicles. No single sequence, formula, or molecular weight defines an exosome, because an exosome is a heterogeneous lipid-bilayer particle rather than a single molecule. Identifiers therefore come from the measurement method: particle size and concentration by nanoparticle tracking analysis (NTA), morphology by transmission electron microscopy (TEM), and cargo identity by protein immunoassay or nucleic-acid sequencing. In the studies below, the measured analytes include podocyte-specific proteins (nephrin, podocalyxin, Wilms' tumour protein WT-1), the microRNA hsa-miR-221-5p, and metabolic or tight-junction proteins.
The work centres on exosome-mediated intercellular signalling, in which cargo transfer between a donor cell and a recipient cell is read out through receptor and pathway families such as EGFR, AMPK/mTOR, and TGF-β/SMAD.
Research Studies
Urinary exosome podocyte proteins and diabetic kidney disease
A clinical study in African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease measures podocyte-specific injury markers in urinary exosomes [1]. The primary objective is to study nephrin, podocalyxin, and WT-1 in exosomes isolated from urine, in participants receiving empagliflozin, finerenone, or combination therapy [1]. Secondary objectives correlate exosome-based podocyte-specific proteins with standard kidney-injury biomarkers including urine albumin/creatinine ratio and estimated GFR, and with systemic inflammatory markers such as interleukins IL-1, IL-6, and IL-12, hs-CRP, and arterial stiffness measurements [1]. This is a human clinical protocol; the measurement is exosome protein immunoassay from urine.
Melanoma exosomal hsa-miR-221-5p and keratinocyte LL-37
In melanoma, spatial suppression of the cathelicidin LL-37 was observed in tumour-adjacent epidermis compared with distal regions in clinical specimens [2]. Melanoma-derived exosomes suppressed keratinocyte LL-37 expression, driven in part by exosomal hsa-miR-221-5p through impaired sustained EGFR signalling [2]. Functionally, keratinocyte-derived LL-37 curtailed melanoma cell migration, invasion, and epithelial-mesenchymal transition, restrained tumour growth in vivo, and was associated with a tumour immune microenvironment enriched in M1 macrophages [2]. The exosome measurement here is cargo microRNA sequencing plus functional assays in cell and animal models.
FGF21-modified ADSC exosomes and fibroblast glycolysis
Adipose-derived mesenchymal stem cells overexpressing fibroblast growth factor 21 were established by genetic engineering, and FGF21-enriched exosomes (Exo@FGF21) were isolated and characterised using transmission electron microscopy and nanoparticle tracking analysis [3]. The study aimed to elucidate how these engineered exosomes promote wound healing by activating fibroblast glycolysis through AMPK/mTOR signalling [3]. Measurement therefore combined physical characterisation (TEM, NTA) with pathway readouts. This work is preclinical.
Cerebrolysin-treated endothelial cell exosomes and permeability
Using an in vitro endothelial permeability assay, a study tested whether exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) affect dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes from untreated cells (Naïve-Exos), with Cerebro-Exos highly enriched in metabolic and tight-junction-related proteins [4]. Cerebro-Exos had a superior effect compared with Naïve-Exos on restoring endothelial integrity impaired by fibrin and tissue plasminogen activator [4]. The measurement is cargo protein profiling in an in vitro model.
Umbilical cord blood stem cells and exosomes in autism spectrum disorder
A 12-month clinical study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3–12 [5]. About 100 children with confirmed autism are randomly assigned to one of two groups; one receives monthly intravenous AdiaVita plus intravenous glutathione for 3 months, and the other receives intravenous glutathione plus a saline placebo infusion for 2 months, with both groups using a topical glutathione spray twice daily at home [5]. Symptoms are tracked with the Autism Treatment Evaluation Checklist completed by a parent and by a therapist or teacher, and safety is monitored through Month 12 [5]. Exosome content is a component of the investigational product rather than a measured analyte.
Neuronal exosomes and exercise-related biomarkers
A study examining the brain-based biological mechanism by which exercise exerts anxiolytic effects measures brain-derived markers of mitochondrial metabolism (acetyl-L-carnitine) and inflammation (interleukin-6) using technology to isolate neuronal exosomes [7]. The measurement approach is exosome isolation from blood followed by analyte quantification. This is a human study protocol.
Wharton's jelly exosomes combined with bone marrow cells in liver cirrhosis
A clinical protocol in patients with liver cirrhosis, irrespective of stage and excluding those with active tumour or other major life-endangering health issues, uses autologous bone marrow-derived mononuclear cells harvested from the same patient under local anaesthesia, followed by cell concentration and viability testing [8]. The final product is combined with a small volume of 2 cc of Wharton's jelly exosomes at 20 billion per dose and administered intravenously [8]. Exosome quantity here is specified as a dose count rather than a measured biomarker.
Regenerative medicine approaches to craniofacial and corneal neuropathic pain
Craniofacial and corneal neuropathic pain are disabling conditions characterised by persistent pain frequently refractory to conventional pharmacologic and interventional therapies, arising from interactions between peripheral nerve injury, neuroinflammation, and maladaptive central sensitisation within trigeminal pathways [6]. A review of regenerative medicine approaches frames these disorders as spanning neuropathic and nociplastic mechanisms and emphasises mechanism-based, patient-stratified treatment strategies [6]. Exosome-based approaches are discussed within this broader regenerative framework; the source is a review rather than a primary measurement study.
Comparison of exosome measurement contexts
| Study | Source of exosomes | Measurement method | Model |
|---|---|---|---|
| [1] | Urine | Podocyte protein immunoassay (nephrin, podocalyxin, WT-1) | Human clinical |
| [2] | Melanoma cell-derived | microRNA cargo (hsa-miR-221-5p) | Clinical specimens, cell and animal |
| [3] | Engineered ADSC | TEM and NTA | Preclinical |
| [4] | Cerebral endothelial cells | Cargo protein profiling | In vitro |
| [7] | Neuronal (blood) | Isolation then analyte quantification | Human clinical |
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Role of Finerenone in African American Veterans With Diabetic Kidney Disease
- [2] Melanoma exosomal hsa-miR-221-5p suppresses keratinocyte LL-37 to promote tumor progression
- [3] FGF21-modified adipose stem cell-derived exosomes promote wound healing by activating fibroblast glycolysis through AMPK/mTOR signaling
- [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability
- [5] Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
- [6] Regenerative Medicine Approaches to Craniofacial and Corneal Neuropathic Pain
- [7] Biomarkers for Exercise
- [8] Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis